-
Je něco špatně v tomto záznamu ?
Proton beam therapy for mediastinal Hodgkin lymphoma: A prospective study of clinical efficacy and safety
K. Dědečková, M. Andrlik, H. Móciková, L. Kaliská, S. Zapletalová, J. Kubeš, S. Al-Hamami, DJ. Cutter, G. Ntentas, V. Vondráček, B. Ondrová, J. Marková, Ľ. Gahérová, L. Mohammadová, V. Procházka, J. Michalka, A. Sýkorová, J. Ďuraš, J. Kořen, M....
Jazyk angličtina Země Irsko
Typ dokumentu časopisecké články
- MeSH
- celková dávka radioterapie MeSH
- dospělí MeSH
- Hodgkinova nemoc * radioterapie mortalita MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- nádory mediastina * radioterapie mortalita MeSH
- prospektivní studie MeSH
- protonová terapie * škodlivé účinky metody MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Proton beam therapy using pencil beam scanning is an advanced radiotherapy technique that utilises proton beams to precisely target tumours. It is known for its enhanced ability in sparing healthy tissue and potentially reducing toxicity. Clinical experience with pencil beam scanning in the treatment of mediastinal Hodgkin lymphoma remains limited. PATIENTS AND METHODS: This study aimed to evaluate the toxicity and outcomes of a prospectively observed cohort. A total of 162 patients were irradiated between May 2013 and December 2020, with a median age of 32 years (range: 18.4-79.2) and followed up until April 2024. The median applied dose was 30 GyE (range: 20-40). Deep inspiration breath hold was used in 146 patients to enhance targeting precision. RESULTS: The disease-free survival, overall survival and local control rates were 95.1 %, 98.8 % and 98.8 %, respectively. The median follow-up was 59.1 months (range: 4-120.1). The most common acute toxicities observed were oesophageal and skin toxicity. Grade 1 oesophageal mucositis occurred in 76 patients (47 %), grade 2 in 16 patients (10 %). Dermatitis of grade 1 and 2 was observed in 65 (40 %) and 4 (3 %) patients respectively. Grade 1 pulmonary toxicity presented in 8 patients (4.9 %), and grade 2 in one patient (0.6 %). The most predominant late toxicity was grade 2 hypothyroidism in 37 patients (23 %). Three patients (1.8 %) underwent coronary interventions during follow-up, and one patient was diagnosed with hepatocellular carcinoma 3 months post-RT. No unexpected acute or late toxicities were observed. CONCLUSION: Proton beam therapy using pencil beam scanning is a safe and effective technique in terms of toxicity and local control, even when irradiating mediastinal targets.
Charles University 1st Faculty of Medicine Praha Czech Republic
Department of Internal Medicine Hematology and Oncology University Hospital Brno Czech Republic
Faculty of Mathematics and Physics Charles University Praha Czech Republic
Faculty of Medicine Masaryk University Brno Czech Republic
Institute of Nuclear and Molecular Medicine Banská Bystrica Slovakia
Nuffield Department of Population Health University of Oxford Oxford UK
Proton Therapy Center Czech Praha Czech Republic
School of Biomedical Engineering and Imaging Sciences King's College London London UK
University Hospital Pilsen Department of Haematology and Oncology Plzeň Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015188
- 003
- CZ-PrNML
- 005
- 20250731090819.0
- 007
- ta
- 008
- 250708e20250510ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.radonc.2025.110931 $2 doi
- 035 __
- $a (PubMed)40355029
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Dědečková, Kateřina $u Proton Therapy Center Czech, Praha, Czech Republic
- 245 10
- $a Proton beam therapy for mediastinal Hodgkin lymphoma: A prospective study of clinical efficacy and safety / $c K. Dědečková, M. Andrlik, H. Móciková, L. Kaliská, S. Zapletalová, J. Kubeš, S. Al-Hamami, DJ. Cutter, G. Ntentas, V. Vondráček, B. Ondrová, J. Marková, Ľ. Gahérová, L. Mohammadová, V. Procházka, J. Michalka, A. Sýkorová, J. Ďuraš, J. Kořen, M. Navrátil, M. Vařejková, T. Doležal, J. Prausová, Czech Hodgkin Lymphoma Study Group
- 520 9_
- $a BACKGROUND: Proton beam therapy using pencil beam scanning is an advanced radiotherapy technique that utilises proton beams to precisely target tumours. It is known for its enhanced ability in sparing healthy tissue and potentially reducing toxicity. Clinical experience with pencil beam scanning in the treatment of mediastinal Hodgkin lymphoma remains limited. PATIENTS AND METHODS: This study aimed to evaluate the toxicity and outcomes of a prospectively observed cohort. A total of 162 patients were irradiated between May 2013 and December 2020, with a median age of 32 years (range: 18.4-79.2) and followed up until April 2024. The median applied dose was 30 GyE (range: 20-40). Deep inspiration breath hold was used in 146 patients to enhance targeting precision. RESULTS: The disease-free survival, overall survival and local control rates were 95.1 %, 98.8 % and 98.8 %, respectively. The median follow-up was 59.1 months (range: 4-120.1). The most common acute toxicities observed were oesophageal and skin toxicity. Grade 1 oesophageal mucositis occurred in 76 patients (47 %), grade 2 in 16 patients (10 %). Dermatitis of grade 1 and 2 was observed in 65 (40 %) and 4 (3 %) patients respectively. Grade 1 pulmonary toxicity presented in 8 patients (4.9 %), and grade 2 in one patient (0.6 %). The most predominant late toxicity was grade 2 hypothyroidism in 37 patients (23 %). Three patients (1.8 %) underwent coronary interventions during follow-up, and one patient was diagnosed with hepatocellular carcinoma 3 months post-RT. No unexpected acute or late toxicities were observed. CONCLUSION: Proton beam therapy using pencil beam scanning is a safe and effective technique in terms of toxicity and local control, even when irradiating mediastinal targets.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a protonová terapie $x škodlivé účinky $x metody $7 D061766
- 650 12
- $a Hodgkinova nemoc $x radioterapie $x mortalita $7 D006689
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a mladiství $7 D000293
- 650 12
- $a nádory mediastina $x radioterapie $x mortalita $7 D008479
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a celková dávka radioterapie $7 D011879
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Andrlik, Michal $u Proton Therapy Center Czech, Praha, Czech Republic. Electronic address: michal.andrlik@ptc.cz
- 700 1_
- $a Móciková, Heidi $u University Hospital Královské Vinohrady, Department of Haematology and Third Faculty of Medicine, Charles University, Praha, Czech Republic
- 700 1_
- $a Kaliská, Lucia $u Proton Therapy Center Czech, Praha, Czech Republic; Institute of Nuclear and Molecular Medicine, Banská Bystrica, Slovakia
- 700 1_
- $a Zapletalová, Simona $u Proton Therapy Center Czech, Praha, Czech Republic
- 700 1_
- $a Kubeš, Jiří $u Proton Therapy Center Czech, Praha, Czech Republic; Department of Health Care Disciplines and Population Protection, Faculty of Biomedical Engineering, Czech Technical University Prague, Kladno, Czech Republic
- 700 1_
- $a Al-Hamami, Sarah $u Proton Therapy Center Czech, Praha, Czech Republic
- 700 1_
- $a Cutter, David J $u Nuffield Department of Population Health, University of Oxford, Oxford, UK; Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK
- 700 1_
- $a Ntentas, Georgios $u Nuffield Department of Population Health, University of Oxford, Oxford, UK; Department of Medical Physics and Clinical Engineering, Guy's and St Thomas' NHS Foundation Trust, London, UK; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK
- 700 1_
- $a Vondráček, Vladimír $u Proton Therapy Center Czech, Praha, Czech Republic; Department of Health Care Disciplines and Population Protection, Faculty of Biomedical Engineering, Czech Technical University Prague, Kladno, Czech Republic
- 700 1_
- $a Ondrová, Barbora $u Proton Therapy Center Czech, Praha, Czech Republic
- 700 1_
- $a Marková, Jana $u University Hospital Královské Vinohrady, Department of Haematology and Third Faculty of Medicine, Charles University, Praha, Czech Republic
- 700 1_
- $a Gahérová, Ľubica $u University Hospital Královské Vinohrady, Department of Haematology and Third Faculty of Medicine, Charles University, Praha, Czech Republic
- 700 1_
- $a Mohammadová, Lekaá $u University Hospital Pilsen, Department of Haematology and Oncology, Plzeň, Czech Republic
- 700 1_
- $a Procházka, Vít $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
- 700 1_
- $a Michalka, Jozef $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Czech Republic; Faculty of Medicine, Masaryk University Brno, Czech Republic
- 700 1_
- $a Sýkorová, Alice $u University Hospital Hradec Králové, The 4th Department of Internal Medicine - Hematology, Hradec Králové, Czech Republic
- 700 1_
- $a Ďuraš, Juraj $u University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Department of Haematooncology, Ostrava, Czech Republic
- 700 1_
- $a Kořen, Jan $u General University Hospital in Praque, 1st Medical Department-Department of Heamatology, Praha, Czech Republic; Charles University, First Faculty of Medicine, Praha, Czech Republic
- 700 1_
- $a Navrátil, Matěj $u Proton Therapy Center Czech, Praha, Czech Republic
- 700 1_
- $a Vařejková, Michaela $u Value Outcomes, Praha, Czech Republic; Faculty of Mathematics and Physics, Charles University, Praha, Czech Republic
- 700 1_
- $a Doležal, Tomáš $u Value Outcomes, Praha, Czech Republic
- 700 1_
- $a Prausová, Jana $u Proton Therapy Center Czech, Praha, Czech Republic
- 710 2_
- $a Czech Hodgkin Lymphoma Study Group
- 773 0_
- $w MED00004049 $t Radiotherapy and oncology $x 1879-0887 $g Roč. 208 (20250510), s. 110931
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40355029 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731090814 $b ABA008
- 999 __
- $a ok $b bmc $g 2366192 $s 1252313
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 208 $c - $d 110931 $e 20250510 $i 1879-0887 $m Radiotherapy and oncology $n Radiother Oncol $x MED00004049
- LZP __
- $a Pubmed-20250708
